Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Phoenix Molecular Designs
About
Phoenix Molecular Designs is a biopharmaceutical company designing precise cancer therapeutics by targeting kinases.
- 11 - 50
Details
- Last Funding Type
- Seed
- Last Funding Money Raised
- $4.99M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2012
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Phoenix Molecular Designs is developing precise cancer therapeutics with a platform technology focused on developing first-in-class kinase inhibitors designed to uniquely target p90 ribosomal S6 kinase (RSK). Their world-renowned leadership team boasts over 100 years of oncology experience from notable affiliations such as Genentech, Pfizer and Eli Lily. The company completed a Phase 1 first-in-human clinical trial with lead asset, PMD-026, as of Oct 2020, treating women with metastatic breast cancer. A Phase 1b mono-therapy trial is now open in triple negative breast cancer (TNBC) in 9 leading medical centers across the United States.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 20, 2019 | Seed | $4.99M | 1 |
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Seed |
